Real-time
Euronext Lisbonne
15:30:24 22/05/2024 BST
|
5-day change
|
1st Jan Change
|
1.5
EUR
|
+15.38%
|
|
+15.38%
|
+15.38%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
69.75
|
98
|
80
|
30
|
44.8
|
26
|
Enterprise Value (EV)
1 |
270.6
|
335
|
325.4
|
275.8
|
293.8
|
246.7
|
P/E ratio
|
29.5
x
|
46
x
|
-5.28
x
|
15.7
x
|
12.3
x
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.1
x
|
0.12
x
|
0.1
x
|
0.04
x
|
0.05
x
|
0.03
x
|
EV / Revenue
|
0.38
x
|
0.42
x
|
0.42
x
|
0.34
x
|
0.35
x
|
0.29
x
|
EV / EBITDA
|
12.6
x
|
9.2
x
|
22.1
x
|
10.4
x
|
9.28
x
|
5.24
x
|
EV / FCF
|
50.6
x
|
11.3
x
|
2,574
x
|
35.5
x
|
45.6
x
|
11.3
x
|
FCF Yield
|
1.98%
|
8.82%
|
0.04%
|
2.82%
|
2.2%
|
8.88%
|
Price to Book
|
0.77
x
|
0.83
x
|
0.76
x
|
0.28
x
|
0.37
x
|
-
|
Nbr of stocks (in thousands)
|
15,500
|
20,000
|
20,000
|
20,000
|
20,000
|
20,000
|
Reference price
2 |
4.500
|
4.900
|
4.000
|
1.500
|
2.240
|
1.300
|
Announcement Date
|
09/05/19
|
04/06/20
|
21/05/21
|
03/05/22
|
04/05/23
|
09/05/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
710.1
|
788.6
|
772.9
|
804.5
|
835.7
|
864.4
|
EBITDA
1 |
21.44
|
36.43
|
14.73
|
26.42
|
31.65
|
47.09
|
EBIT
1 |
12.66
|
25.72
|
4.319
|
16.62
|
18.22
|
33.66
|
Operating Margin
|
1.78%
|
3.26%
|
0.56%
|
2.07%
|
2.18%
|
3.89%
|
Earnings before Tax (EBT)
1 |
12.26
|
25.68
|
-8.153
|
19.84
|
17.17
|
21.45
|
Net income
1 |
3.048
|
2.129
|
-15.16
|
1.916
|
3.647
|
10.31
|
Net margin
|
0.43%
|
0.27%
|
-1.96%
|
0.24%
|
0.44%
|
1.19%
|
EPS
2 |
0.1524
|
0.1064
|
-0.7582
|
0.0958
|
0.1824
|
-
|
Free Cash Flow
1 |
5.349
|
29.54
|
0.1264
|
7.778
|
6.45
|
21.91
|
FCF margin
|
0.75%
|
3.75%
|
0.02%
|
0.97%
|
0.77%
|
2.54%
|
FCF Conversion (EBITDA)
|
24.95%
|
81.11%
|
0.86%
|
29.44%
|
20.38%
|
46.53%
|
FCF Conversion (Net income)
|
175.5%
|
1,387.84%
|
-
|
406.02%
|
176.85%
|
212.49%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/05/19
|
04/06/20
|
21/05/21
|
03/05/22
|
04/05/23
|
09/05/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
201
|
237
|
245
|
246
|
249
|
221
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
9.37
x
|
6.506
x
|
16.66
x
|
9.301
x
|
7.868
x
|
4.687
x
|
Free Cash Flow
1 |
5.35
|
29.5
|
0.13
|
7.78
|
6.45
|
21.9
|
ROE (net income / shareholders' equity)
|
5.35%
|
10.4%
|
-3.76%
|
5.83%
|
6.75%
|
9.2%
|
ROA (Net income/ Total Assets)
|
1.51%
|
2.85%
|
0.45%
|
1.74%
|
1.85%
|
3.36%
|
Assets
1 |
201.2
|
74.77
|
-3,345
|
110.2
|
197.1
|
307
|
Book Value Per Share
2 |
5.870
|
5.900
|
5.230
|
5.400
|
6.080
|
-
|
Cash Flow per Share
2 |
0
|
0.6700
|
0.9900
|
0
|
0
|
-
|
Capex
1 |
2.07
|
2.68
|
1.58
|
1.17
|
3.03
|
6.48
|
Capex / Sales
|
0.29%
|
0.34%
|
0.2%
|
0.15%
|
0.36%
|
0.75%
|
Announcement Date
|
09/05/19
|
04/06/20
|
21/05/21
|
03/05/22
|
04/05/23
|
09/05/24
|
|
1st Jan change
|
Capi.
|
---|
| +15.38% | 32.47M | | -31.33% | 11.31B | | +15.73% | 6.47B | | -30.66% | 6.32B | | -8.33% | 6.09B | | +74.00% | 4.95B | | -1.61% | 4.67B | | -6.00% | 3.95B | | -14.62% | 3.34B | | -12.02% | 2.92B |
Other Drug Retailers
|